Jeena Sikho Lifecare Ltd

- Approved Q1 FY2025-26 unaudited results showing profit after tax Rs. 51.31 Cr standalone, Rs. 51.27 Cr consolidated. - Revenue grew to Rs. 174.29 Cr. - Statutory auditor KRA & Co resigned; Walker Chandiok LLP appointed. - Shares migrated from NSE SME to Main Board.

📊 Quarterly Financial Results & Auditor Change Update

Financial Results

• Q1 FY2025-26 standalone revenue: Rs. 174.29 crore, up from Rs. 139.02 crore (Q1 FY2024).
• Profit after tax: Rs. 51.31 crore standalone, Rs. 51.27 crore consolidated.
• Basic EPS: Rs. 4.13 for the quarter (not annualized).

Business Segment

• Operations in Trading of Ayurvedic Medicines and Ayurvedic Therapies only.
• Adoption of Indian Accounting Standards (Ind AS) from FY2025-26 impacts accounting methods.

Change of Auditors

• Resignation of statutory auditors M/s KRA & Co on 13th Aug 2025.
• Appointment of M/s Walker Chandiok & Co LLP to fill vacancy and recommended for a 5-year term.

Listing and Share Capital

• Shares migrated from NSE SME Emerge Platform to Main Board of BSE/NSE on 11th Aug 2025.
• Equity shares split on 12th June 2025: 1 share of Rs. 10 face value subdivided into 5 shares of Rs. 2 face value each.

Implications

• Financial results offer insights on company's earnings and accounting changes.
• Auditor change indicates update in financial oversight.
• Migration to Main Board may enhance company's visibility and investor confidence.

This update provides financial and compliance information useful for investors to understand current status.